Epic Sciences receives CAP accreditation.
Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory. The CAP Laboratory Accreditation Program is recognized by the United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.
“Our investment in a high-throughput, CLIA/CAP laboratory will give drug developers and academic investigators alike the ability to scale Epic Sciences’ circulating tumor cell (CTC) based liquid biopsy tests from small observational studies to large Phase III trials,” said Murali Prahalad, Ph.D., president and CEO of Epic Sciences.
Epic Sciences has analyzed more than 10,000 blood samples from cancer patients and is in use in more than 58 active clinical trials. The identification and characterization of CTCs from a liquid biopsy, allows for the development of companion diagnostics that match the right patients to the right therapies at the right time.
Epic Sciences’ “no cell left behind” platform identifies CTCs in an unbiased manner, without enrichment or depletion on any parameter. It has the capability to detect all categories of CTCs in the blood, and can analyze single CTCs for genomic, proteomic, and morphologic markers.
About Epic Sciences
At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.
We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.
For more information, visit epicsciences.com.
Stay in touch on LinkedIn, on Twitter@EpicSciences and Facebook.com/EpicSciences.